Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 27

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 27
---
) |
| Number issued and outstanding after this offering and private placement                    |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     29,171,429(1)(3) |
| Rights:                                                                                    |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Number included in the private units to be sold in a private placement simultaneously with 
 this offering                                                                              |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           400,000(1) |
| Number issued and outstanding after this offering and private                              
 placement                                                                                  |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        20,400,000(1) |
| Terms of Rights                                                                            |     | Except in cases where we are not the surviving company in a business combination, each holder of a public right will automatically receive one-eighth (1/8) of an ordinary share upon consummation of our initial business combination. In the event we will not be the surviving company upon completion of our initial business combination, each holder of a right will be required to affirmatively convert its rights in order to receive the one-eighth (1/8) of one ordinary share underlying each right upon consummation of the business combination. We will not issue fractional shares in connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of Cayman Islands law. As a result, you must hold rights in multiples of eight in order to receive shares for all of your rights upon closing of a business combination. If we are unable to complete an initial business combination within the required time period and we redeem the public shares for the funds held in the trust account, holders of rights will not receive any of such funds for their rights and the rights will expire worthless. |

____________ (1)Assumes no exercise of the underwriters’ over -allotmentoption and the surrender and forfeiture by our initial shareholders of 1,285,714 founder shares. (2)Consists of 9,857,143 founder shares, which includes up to 1,285,714 founder shares that are subject to surrender and forfeiture by our initial shareholders depending on the extent to which the underwriters’ over -allotmentoption is exercised. (3)Includes 20,000,000 public shares, 400,000 private shares, 200,000 representative shares and 8,571,429 founder shares.

14

| Founder shares |     | On June